Clee Medical SA

Based in Switzerland, Clee Medical SA specializes in advanced neuroimaging solutions aimed at enhancing the precision and efficiency of neurosurgical procedures through innovative real-time imaging technology. Clee Medical SA provides advanced neuroimaging solutions and was co-founded in 2024 in Geneva, Switzerland by Matthew Lapinski and Abed Hammoud . In February 2026, Clee Medical SA raised a seed funding round led by new investor High-Tech Gruenderfonds, with participation from other new investors FONGIT, Kickfund, Venture Kick, and Zürcher Kantonalbank. Returning investor Wyss Center for Bio and Neuro Engineering also participated in the round.

Clee Medical SA specializes in pioneering neuroimaging solutions designed to enhance the precision and efficiency of neurosurgical procedures. The company's core offering is a real-time intraoperative brain imaging platform that provides ultra-high-resolution visualization without the need for contrast agents or radiation. This innovative technology enables surgeons to detect blood vessels and tissues with a clarity of 15 micrometers, significantly surpassing traditional MRI capabilities. The platform integrates seamlessly with existing neurosurgical equipment, making it easier for medical professionals to incorporate it into current surgical routines.

Clee Medical primarily targets healthcare providers, including hospitals and surgical centers, across Europe and North America, aiming to improve patient outcomes and expand surgical capacity through its advanced neurotech solutions. Clee Medical's revenue generation model is rooted in B2B transactions, primarily involving healthcare institutions that adopt its imaging technology. The company offers its flagship product through direct sales to hospitals and surgical centers, facilitating real-time imaging during neurosurgical procedures. Revenue is realized through one-time purchases of the imaging systems, along with potential service agreements for ongoing support and maintenance.

Additionally, the company may explore partnerships with neurosurgical departments to integrate its products into established workflows, thereby enhancing surgical outcomes. This model reflects a commitment to delivering innovative solutions within the medical community, specifically targeting clients who require advanced neurosurgical tools and techniques. In February 2026, Clee Medical SA raised a seed funding round led by new investor High-Tech Gruenderfonds, with participation from other new investors FONGIT, Kickfund, Venture Kick, and Zürcher Kantonalbank. Returning investor Wyss Center for Bio and Neuro Engineering also participated in the round.

The company will use the funding to advance its real-time brain imaging system, run clinical studies, conduct first-in-human trials, and complete technical testing.